Internal efficiency development to continue 34% adj.
CEO highlighted importance of product innovation New Bangladesh factory remains core part of strateg...
Earnings growth to pick up from Q2'25e Estimates down given more cautious view on activity pick-up 2...
Several growth drivers from product innovation and portfolio expansion Quarterly volatility is part ...
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) har nyligen rapporterat årets f...
Redeye takes a positive stance on Sivers Semiconductors' recent renewal of its debt financing, secur...
Redeye provides an update on Acarix following its Q1 report, which showed continued growth in revenu...
Q1 was an active quarter for Cantargia. Among other things, positive multiple ascending dose results...
Redeye comments on Enviro’s Q1 report, which presented no real surprises.
Q1 sales 20% below cons, partly driven by Brazil impact Adj.
Redeye provides an initial take following the release of SenzaGen’s Q1 2025 report.
Q1 EBIT SEK 164m (vs. ABSCe 253m) Pome sales biggest contributor, Stor-Skälsjön completed Pome 75% c...
Redeye provides its initial take on Surgical Science’s Q1 2025 report, which mostly beat our estimat...
Redeye updates its estimates and fair value range following CoinShares' Q1 2025 report.
Redeye revises its estimates for Smart Eye following interesting industry developments.
